Xin Huang
Managing Partner
Healthcare
Mr. Xin Huang is Managing Partner of Co-Win Ventures. He started Co-Win Ventures' healthcare practice and has since led the investment. He has over 20 years of experience in clinical medicine, translational research, healthcare management consulting and venture capital investment. His profession in venture capital started in 2010.
Mr. Huang has led and participated in deals such as CytekBio (CTKB.US), Connect Biopharma (CNTB.US), Thrive (acquired by EXAS.US), Celsius (acquired by AbbVie), PGDx (acquired by Labcorp), Immorna, Aucoda Pharmaceuticals, D1 Med Technology, Snipet, CytoChip, Complete Omics, Leads Biolabs, CF PharmTech, 3DMed, and etc.
In 2024, Mr. Huang was named the “Healthcare Investor of the Year” by Houyue Capital, marking his fourth time receiving this prestigious honor. Additionally, he has been named to the China TOP 30 Angel Investors by Entrepreneurship Foundation & CV INFO and the TOP 50 Most Influential Investors by CHC & Citic Securities for 2021.
Prior to joining Co-Win Ventures, Mr. Huang served as Management Consultant of BCG and Senior Investment Manager of Omaha Capital.
Mr. Huang holds an M.D. from Peking Union Medical College, and a Ph.D. from Johns Hopkins University. He was ranked No.1 in the National College Entrance Exam in China in 1995.
In 2024, Mr. Huang was named the “Healthcare Investor of the Year” by Houyue Capital, marking his fourth time receiving this prestigious honor. Additionally, he has been named to the China TOP 30 Angel Investors by Entrepreneurship Foundation & CV INFO and the TOP 50 Most Influential Investors by CHC & Citic Securities for 2021.
Prior to joining Co-Win Ventures, Mr. Huang served as Management Consultant of BCG and Senior Investment Manager of Omaha Capital.
Mr. Huang holds an M.D. from Peking Union Medical College, and a Ph.D. from Johns Hopkins University. He was ranked No.1 in the National College Entrance Exam in China in 1995.